AlgoTx Announces Results of its Phase 2 “ACT” Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

AlgoTx Announces First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Rare Disease Erythromelalgia

AlgoTx Progresses ATX01 in Two Indications

AlgoTx wins France Biotech’s 2023 ESG HealthTech Trophy

AlgoTx Raises €20M to Conduct ATX01’s Phase 2 Program in Peripheral Neuropathic Pain

AlgoTx Announces Initiation of Global Phase 2 Clinical Trial of ATX01 for the Relief of Pain in Chemotherapy-induced Peripheral Neuropathy in Adults

FDA Grants AlgoTx IND Clearance for Phase 2 Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

AlgoTx appoints Agathe Nadolny Chief Project Management Officer

AlgoTx completes Phase I for peripheral neuropathy program ATX01, poised for Phase II initiation in 2022.

AlgoTx appoints Edmund Harrigan and Scott Byrd to the Board of Directors.

ATX01 enters Clinical Development

AlgoTx Receives Regulatory Approval to Initiate Clinical Development of ATX01

AlgoTx raises €12M to take ATX01 into clinical development in chemotherapy-induced peripheral neuropathy

Analgesic Effects of Topical Amitriptyline in Patients with CIPN: Mechanistic Insights from Studies in Mice

AlgoTx in Business Worldwide’s Top 20 Innovative Companies

AlgoTx featured in Business Worldwide Magazine

AlgoTx appoints Etienne Bienfait Fin&Admin Manager

FDA Grants ATX01 Orphan Drug Designation in Erythromelalgia

AlgoTx names Philippe Picaut Chief Scientific Officer

Roy Freeman joins AlgoTx’s Scientific Advisory Board.

AlgoTx receives 0.5 M€ boost from BPIfrance

AlgoTx appoints Alain Eschalier and Axel Le Cesne to Scientific Advisory Board

AlgoTx appoints Jean-François Labbé, Hugues Le Bret and Fabrice Aurousseau to Board of Directors

AlgoTx raises 2.6M€ towards pre-clinical development of ATX01